Advanced search
Publication Cover
Molecular & Cellular Oncology Volume 5, 2018 - Issue 5
Submit an article Journal homepage
1,404
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma

Azad SaeiGenome Institute of Singapore, A*STAR, Singapore;Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, SingaporeCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-1000-2953View further author information
ORCID Icon &
Pieter Johan Adam EichhornCancer Science Institute of Singapore, National University of Singapore, Singapore;Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore;School of Pharmacy and Biomedical Sciences, Curtin University, Perth, AustraliaORCID Iconhttp://orcid.org/0000-0001-5840-943XView further author information
ORCID Icon
Article: e1497862 | Received 29 Jun 2018, Accepted 04 Jul 2018, Published online: 05 Sep 2018

References

  • Caunt CJ, Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. FEBS J. 2013;280(2):489–504. doi:10.1111/j.1742-4658.2012.08716.x.
  • Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al., Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596–599. doi:10.1038/nature09454.
  • Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013;19(11):1401–1409. doi:10.1038/nm.3392.
  • Kumari N, Jaynes PW, Saei A, Iyengar PV, Richard JLC, Eichhorn PJA. The roles of ubiquitin modifying enzymes in neoplastic disease. Biochim Biophys Acta. 2017.
  • Saei A, Palafox M, Benoukraf T, Kumari N, Jaynes PW, Iyengar PV, Muñoz-Couselo E, Nuciforo P, Cortés J, Nötzel C, et al. Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. J Exp Med. 2018. doi:10.1084/jem.20171960.
  • Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nature Reviews Cancer. 2008;8(2):83. doi:10.1038/nrc2290.
  • Schülein-Völk C, Wolf E, Zhu J, Xu W, Taranets L, Hellmann A, Jänicke LA, Diefenbacher ME, Behrens A, Eilers M, et al., Dual regulation of Fbw7 function and oncogenic transformation by Usp28. Cell Rep. 2014;9(3):1099–1109. doi:10.1016/j.celrep.2014.09.057.
  • Diefenbacher ME, Popov N, Blake SM, Schülein-Völk C, Nye E, Spencer-Dene B, Jaenicke LA, Eilers M, Behrens A. The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer. J Clin Invest. 2014;124(8):3407–3418. doi:10.1172/JCI73733.
  • Aydin IT, Melamed RD, Adams SJ, Castillo-Martin M, Demir A, Bryk D, Brunner G, Cordon-Cardo C, Osman I, Rabadan R, et al., FBXW7 mutations in melanoma and a new therapeutic paradigm. J Natl Cancer Inst. 2014;106(6):dju107. doi:10.1093/jnci/dju061.
  • Ritt DA, Abreu-Blanco MT, Bindu L, Durrant DE, Zhou M, Specht SI, Stephen AG, Holderfield M, Morrison DK., Inhibition of Ras/Raf/MEK/ERK pathway signaling by a stress-induced phospho-regulatory circuit. Molecular Cell. 2016;64(5):875–887. doi:10.1016/j.molcel.2016.10.029.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.